Status:
RECRUITING
The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Cardiovascular Risk
Prostate Cancer
Eligibility:
MALE
18-80 years
Brief Summary
Prostate cancer is characterised by its slow progression nature, and even for metastatic disease, the 5-year survival is up to 30%. While ADT can effectively control disease, there is increasing evide...
Detailed Description
Prostate Cancer (PCa) and androgen deprivation therapy (ADT) PCa is the most common cancer and the second leading cancer death in adult male globally. In Hong Kong, it is one of the most rapidly incre...
Eligibility Criteria
Inclusion
- Adult men 18-80 years old
- With histological proven prostate cancer or clinically diagnosed to have prostate cancer,
- Planned for ADT for at least 1 year
Exclusion
- Subjects with established major atherosclerotic cardiovascular disease (ASCVD) as defined by a recent acute coronary syndrome within the past 12 months, a history of myocardial infarction other than the recent acute coronary syndrome event, a history of ischemic stroke, and symptomatic peripheral arterial disease (defined as history of claudication with ankle-brachial index \<0.85 or previous revascularization or amputation
- Prior neoadjuvant or adjuvant hormone therapy within 1 year before
- Refuse or unable to give written informed consent
- Participation in an investigational program with interventions outside of routine clinical practice
Key Trial Info
Start Date :
December 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2029
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT06163924
Start Date
December 10 2023
End Date
March 31 2029
Last Update
May 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong